Company news: Valeant and Regeneron

Share this article:
Weeks after bringing Medicis into the fold, Valeant is once again expanding its portfolio. The Canadian company announced Monday it scooped up rights to QLT's drug Visudyne for $112.5 million. The drug is used to treat leaky blood vessels associated with wet age-related macular degeneration. The company said in a statement that the upfront payment breaks down into $62.5 million for US rights and $50 million for non-US rights, which had respective sales of about $21 million and $14 million last year. The deal also includes an agreement to pay a $5 million contingency fee related to QLT's laser program in the US and a $15 contingency payment for the same program outside of the US.

The FDA has cleared Regeneron's Eylea for an additional use. The injection, which was initially approved for wet age-related macular degeneration, has now been given the all-clear for macular edema following central retinal vein occlusion. The approval was based on data from Phase III Copernicus and Galileo studies which had a goal of patients gaining the ability to see at least 15 letters of Best Corrected Visual Acuity after 24 weeks.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.